Unknown

Dataset Information

0

Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.


ABSTRACT: We describe here design, synthesis, and biological evaluation of a series of highly potent HIV-1 protease inhibitors containing stereochemically defined and unprecedented tricyclic furanofuran derivatives as P2 ligands in combination with a variety of sulfonamide derivatives as P2' ligands. These inhibitors were designed to enhance the ligand-backbone binding and van der Waals interactions in the protease active site. A number of inhibitors containing the new P2 ligand, an aminobenzothiazole as the P2' ligand and a difluorophenylmethyl as the P1 ligand, displayed very potent enzyme inhibitory potency and also showed excellent antiviral activity against a panel of highly multidrug-resistant HIV-1 variants. The tricyclic P2 ligand has been synthesized efficiently in an optically active form using enzymatic desymmetrization of meso-1,2-(dihydroxymethyl)cyclohex-4-ene as the key step. We determined high-resolution X-ray structures of inhibitor-bound HIV-1 protease. These structures revealed extensive interactions with the backbone atoms of HIV-1 protease and provided molecular insights into the binding properties of these new inhibitors.

SUBMITTER: Ghosh AK 

PROVIDER: S-EPMC7425579 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.

Ghosh Arun K AK   Kovela Satish S   Osswald Heather L HL   Amano Masayuki M   Aoki Manabu M   Agniswamy Johnson J   Wang Yuan-Fang YF   Weber Irene T IT   Mitsuya Hiroaki H  

Journal of medicinal chemistry 20200429 9


We describe here design, synthesis, and biological evaluation of a series of highly potent HIV-1 protease inhibitors containing stereochemically defined and unprecedented tricyclic furanofuran derivatives as P2 ligands in combination with a variety of sulfonamide derivatives as P2' ligands. These inhibitors were designed to enhance the ligand-backbone binding and van der Waals interactions in the protease active site. A number of inhibitors containing the new P2 ligand, an aminobenzothiazole as  ...[more]

Similar Datasets

| S-EPMC6044451 | biostudies-literature
| S-EPMC3800042 | biostudies-literature
| S-EPMC9081228 | biostudies-literature
| S-EPMC6711809 | biostudies-literature
| S-EPMC6541917 | biostudies-literature
| S-EPMC4607586 | biostudies-literature
| S-EPMC4666783 | biostudies-literature
| S-EPMC2797486 | biostudies-literature
| S-EPMC5896574 | biostudies-literature
| S-EPMC5647257 | biostudies-literature